Prime Medicine, Inc. (PRME): Cash & Equivalents
$63.03M
As of 2025-12-31
$47.45M
As of 2026-06-30
-30.5%
3-year compound annual growth
+11.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $63.03M | -65.5% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $182.48M | +338.9% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $41.57M | -77.8% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $187.62M | +1.2% | 2024-03-01, Balance as of period end |
| 2021-12-31 | $185.42M | +401.5% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $36.98M | n/a | 2023-03-09, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $63.03M | -65.5% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $347.56M | +16.5% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
| Curis Inc (CRIS) | 2025-12-31 | $5.06M | -74.7% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $319.77M | +130.0% |
Compare PRME, CGON, DBVT, CRSP side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗